http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3840772-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_087bed7abab91ae0f927879f9fe8b273
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B3-102
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1891
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B3-1241
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-204
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B3-102
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
filingDate 2019-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c89425e4d0523b66e6726ee9a344fb3b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8dd26f95b2cb9a4d7b27cdf95556c387
publicationDate 2021-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-3840772-A1
titleOfInvention Non-leaking or minimally-leaking choroidal or retinal revascularization
abstract Disclosed herein include methods, kits, formulations, and compositions for increasing choroidal or retinal perfusion or promoting non-leaking or minimally-leaking choroidal or retinal revascularization in a subject in need thereof. An effective amount of an angiogenesis factor (e.g., a pro-angiogenic factor and/or a vascular maturation factor) can be administered to the subject.
priorityDate 2018-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406705
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87200209
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID227354491
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16850
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226412265
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5282412

Total number of triples: 34.